Published in Antimicrob Agents Chemother on October 01, 1976
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother (1993) 8.36
Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob Agents Chemother (1978) 5.94
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother (1986) 4.97
Antifungal susceptibility tests. Antimicrob Agents Chemother (1987) 4.76
Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother (1991) 4.36
In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob Agents Chemother (1989) 4.00
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother (1982) 3.91
Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother (1997) 3.78
Analysis of pH and buffer effects on flucytosine activity in broth dilution susceptibility testing of Candida albicans in two synthetic media. Antimicrob Agents Chemother (1984) 3.74
Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrob Agents Chemother (1994) 3.72
Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. Postgrad Med J (1979) 3.55
Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome. J Clin Microbiol (1986) 3.52
Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts. J Clin Microbiol (1986) 3.40
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother (1986) 3.38
Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents. Antimicrob Agents Chemother (1992) 3.04
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother (1997) 3.02
In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother (1997) 3.01
In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol (1988) 2.88
Variability of agar dilution-replicator method of yeast susceptibility testing. Antimicrob Agents Chemother (1979) 2.84
Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol (1994) 2.81
Problems in the laboratory assessment of antifungal activity. Postgrad Med J (1979) 2.43
Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother (2004) 2.28
Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother (1982) 2.28
Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother (2003) 2.27
Quantitative microculture system with standardized inocula for strain typing, susceptibility testing, and other physiologic measurements with Candida albicans and other yeasts. J Clin Microbiol (1991) 2.21
Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans. J Clin Microbiol (1995) 2.16
Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. Antimicrob Agents Chemother (1989) 1.78
Analysis of growth characteristics of filamentous fungi in different nutrient media. J Clin Microbiol (2001) 1.68
Estrogens inhibit mycelium-to-yeast transformation in the fungus Paracoccidioides brasiliensis: implications for resistance of females to paracoccidioidomycosis. Infect Immun (1984) 1.65
pH and other effects on the antifungal activity of cilofungin (LY121019). Antimicrob Agents Chemother (1989) 1.60
In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother (1993) 1.58
Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans. Antimicrob Agents Chemother (1996) 1.58
Broth dilution testing of Candida albicans susceptibility to ketoconazole. Antimicrob Agents Chemother (1987) 1.57
Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens. Antimicrob Agents Chemother (1989) 1.53
Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother (1983) 1.37
Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob Agents Chemother (1995) 1.35
Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans. Antimicrob Agents Chemother (1988) 1.31
Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother (1987) 1.27
Azole resistance in Candida. Eur J Clin Microbiol Infect Dis (1997) 1.23
Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis. Antimicrob Agents Chemother (1990) 1.22
Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Antimicrob Agents Chemother (1984) 1.21
Comparison of three methods of determining MICs for filamentous fungi using different end point criteria and incubation periods. Antimicrob Agents Chemother (2000) 1.21
Activity of ICI 195,739, a new oral triazole, compared with that of ketoconazole in the therapy of experimental murine blastomycosis. Antimicrob Agents Chemother (1989) 1.19
In vitro studies of activities of some antifungal agents against Candida albicans ATCC 10231 by the turbidimetric method. Antimicrob Agents Chemother (1992) 1.09
Activities of the modified polyene N-D-ornithyl amphotericin methyl ester and the azoles ICI 153066, Bay n 7133, and Bay l 9139 compared with those of amphotericin B and ketoconazole in the therapy of experimental blastomycosis. Antimicrob Agents Chemother (1985) 1.06
Activity of compound G2 isolated from alfalfa roots against medically important yeasts. Antimicrob Agents Chemother (1986) 1.05
Two-site comparison of broth microdilution and semisolid agar dilution methods for susceptibility testing of Cryptococcus neoformans in three media. J Clin Microbiol (1993) 1.03
Effects of temperature on anti-Candida activities of antifungal antibiotics. Antimicrob Agents Chemother (1993) 1.01
Synergistic interaction of trimethoprim and sulfamethoxazole on Paracoccidioides brasiliensis. Antimicrob Agents Chemother (1982) 0.98
Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. Eur J Clin Microbiol Infect Dis (1997) 0.93
Rapid microdilution-colorimetric assay for yeast susceptibility to fluorocytosine. Antimicrob Agents Chemother (1977) 0.92
In vitro evaluation of various antifungal agents alone and in combination by using an automatic turbidimetric system combined with viable count determinations. Antimicrob Agents Chemother (1986) 0.89
SCH 39304 in the treatment of acute or established murine pulmonary blastomycosis. Antimicrob Agents Chemother (1991) 0.86
Factors affecting griseofulvin susceptibility testing of Trichophyton rubrum in microcultures. J Clin Microbiol (1982) 0.85
Lack of in vitro resistance of Candida albicans to ketoconazole, itraconazole and clotrimazole in women treated for recurrent vaginal candidiasis. Genitourin Med (1993) 0.83
Effect of ketoconazole in combination with other inhibitors of sterol synthesis on fungal growth. Antimicrob Agents Chemother (1985) 0.81
In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum. Antimicrob Agents Chemother (1994) 0.80
In vitro susceptibility of Prototheca spp. to gentamicin. Antimicrob Agents Chemother (1991) 0.78
A cephalosporin active in vivo against Nocardia: efficacy of cefotaxime in murine model of acute pulmonary nocardiosis. J Hyg (Lond) (1983) 0.78
Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test. J Clin Microbiol (1997) 0.75
Comparative antifungal activity of cilofungin (LY121019) against Candida species, including evaluation of susceptibility testing method. Can J Infect Dis (1992) 0.75
Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis (1972) 7.47
Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine. Antimicrob Agents Chemother (1973) 5.84
A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis (1969) 5.58
Chemotherapy of systemic mycoses (first of two parts). N Engl J Med (1974) 4.20
Patterns of Candida endocarditis following cardiac surgery: Importance of early diagnosis and therapy (an analysis of 91 cases). Prog Cardiovasc Dis (1974) 2.95
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice. J Infect Dis (1975) 2.53
Application of DNA typing methods to epidemiology and taxonomy of Candida species. J Clin Microbiol (1987) 13.21
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother (1993) 8.36
A Candida albicans dispersed, repeated gene family and its epidemiologic applications. Proc Natl Acad Sci U S A (1988) 7.75
Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis (1991) 6.43
Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob Agents Chemother (1978) 5.94
Direct allelic variation scanning of the yeast genome. Science (1998) 5.90
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother (1986) 4.97
Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother (1995) 4.92
Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 4.75
Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis (1983) 4.42
In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob Agents Chemother (1989) 4.00
Miconazole in coccidiodomycosis. II. Therapeutic and pharmacologic studies in man. Am J Med (1976) 3.91
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother (1982) 3.91
Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother (1982) 3.90
Treatment of invasive aspergillosis with itraconazole. Am J Med (1989) 3.87
Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters. Am Rev Respir Dis (1978) 3.75
Analysis of pH and buffer effects on flucytosine activity in broth dilution susceptibility testing of Candida albicans in two synthetic media. Antimicrob Agents Chemother (1984) 3.74
Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med (1991) 3.69
Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. Postgrad Med J (1979) 3.55
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother (1997) 3.02
Miconazole in coccidioidomycosis. I. Assays of activity in mice and in vitro. J Infect Dis (1975) 2.99
Variability of agar dilution-replicator method of yeast susceptibility testing. Antimicrob Agents Chemother (1979) 2.84
Restriction endonuclease analysis of total cellular DNA of Aspergillus fumigatus isolates of geographically and epidemiologically diverse origin. J Infect Dis (1990) 2.66
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med (1994) 2.60
Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother (1990) 2.49
The role of understaffing in central venous catheter-associated bloodstream infections. Infect Control Hosp Epidemiol (1996) 2.44
Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med (1994) 2.44
Genetic characterization of pathogenic Saccharomyces cerevisiae isolates. Genetics (1994) 2.41
In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis (1992) 2.41
Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts. Antimicrob Agents Chemother (1990) 2.37
Analysis of Candida albicans phenotypes from different geographical and anatomical sources. J Clin Microbiol (1983) 2.33
Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med (1982) 2.25
The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis (2001) 2.25
Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother (1992) 2.22
Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol (1996) 2.19
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea. J Clin Microbiol (1999) 2.15
Treatment of mycoses with itraconazole. Ann N Y Acad Sci (1988) 2.11
Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother (1997) 2.07
Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med (1992) 2.01
Ketoconazole blocks testosterone synthesis. Arch Intern Med (1982) 2.01
Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest (1991) 2.00
Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies. Am J Med (1976) 1.93
Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med (1996) 1.91
Distribution of a corticosteroid-binding protein in Candida and other fungal genera. J Gen Microbiol (1983) 1.86
Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother (1988) 1.85
Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med (1993) 1.83
Recombinant and natural gamma-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immun (1985) 1.82
Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis. Antimicrob Agents Chemother (1990) 1.81
Postexposure varicella management of nonimmune personnel: an alternative approach. Infect Control Hosp Epidemiol (1994) 1.77
Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis (1993) 1.76
Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med (1989) 1.76
Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med (1973) 1.73
Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories. Diagn Microbiol Infect Dis (1994) 1.73
Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination. Proc Natl Acad Sci U S A (1972) 1.73
A five-year study of needlestick injuries: significant reduction associated with communication, education, and convenient placement of sharps containers. Infect Control Hosp Epidemiol (1992) 1.72
Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography. Antimicrob Agents Chemother (1991) 1.72
Saccharomyces cerevisiae virulence phenotype as determined with CD-1 mice is associated with the ability to grow at 42 degrees C and form pseudohyphae. Infect Immun (1994) 1.72
Viral infections in man associated with acquired immunological deficiency states. Fed Proc (1972) 1.70
Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae. J Infect Dis (1994) 1.69
Susceptibility of Candida albicans to flucytosine when tested in different formulations of yeast nitrogen base broth. Diagn Microbiol Infect Dis (1986) 1.68
Estrogens inhibit mycelium-to-yeast transformation in the fungus Paracoccidioides brasiliensis: implications for resistance of females to paracoccidioidomycosis. Infect Immun (1984) 1.65
Interferon, antibody, and other host factors in herpes zoster. J Clin Invest (1972) 1.64
Pathogen factors and host factors in murine pulmonary blastomycosis. Mycopathologia (1982) 1.61
Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother (1991) 1.61
pH and other effects on the antifungal activity of cilofungin (LY121019). Antimicrob Agents Chemother (1989) 1.60
Emerging pathogens. Med Mycol (2000) 1.59
Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med (1991) 1.58
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis (1992) 1.58
In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother (1993) 1.58
Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med (2000) 1.58
Treatment of fungal meningitis with miconazole. Arch Intern Med (1977) 1.57
Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol (1990) 1.57
Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens. Antimicrob Agents Chemother (1989) 1.53
Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis (2000) 1.53
Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. Rev Infect Dis (1987) 1.53
Bioassays for itraconazole blood levels: an interlaboratory collaborative study. J Antimicrob Chemother (1999) 1.52
Utility of the triazole D0870 in the treatment of experimental systemic coccidioidomycosis. J Med Vet Mycol (1994) 1.52
Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob Agents Chemother (1992) 1.52
Spontaneous mutant of Blastomyces dermatitidis attenuated in virulence for mice. Sabouraudia (1982) 1.51
High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med (1984) 1.51
Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob Agents Chemother (1992) 1.50
Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother (1991) 1.49
Coccidioidomycosis at a university health service. Am Rev Respir Dis (1985) 1.48
Bordetella pertussis adenylate cyclase: effects of affinity-purified adenylate cyclase on human polymorphonuclear leukocyte functions. Infect Immun (1987) 1.48
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Estradiol binds to a receptor-like cytosol binding protein and initiates a biological response in Paracoccidioides brasiliensis. Proc Natl Acad Sci U S A (1983) 1.47